INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94701, 'Sodium bicarbonate', 'Minocycline', 'Moderate', 'INTERVAL: Alkalinization of the urine may decrease the plasma concentration of some tetracyclines. The mechanism is not completely understood, but may involve increased renal elimination of tetracyclines when the urine becomes alkalinized.', 'DDInter', 'If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).', 'Excretion', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94805/', '', 'Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Tigecycline, Sarecycline, Omadacycline, Eravacycline, Neomycin', 'Sorbitol, Sulfamethizole, Sodium chloride, Chlorhexidine, Neomycin, Arginine, Sodium glycerophosphate, Sodium phosphate, monobasic, Sodium chloride, Potassium acetate, Ammonium chloride', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94702, 'Minocycline', 'Lactic acid', 'Moderate', 'INTERVAL: Alkalinization of the urine may decrease the plasma concentration of some tetracyclines. The mechanism is not completely understood, but may involve increased renal elimination of tetracyclines when the urine becomes alkalinized.', 'DDInter', 'If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).', 'Excretion', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94806/', '', 'Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Methylprednisolone, Azelaic acid, More', 'Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Mitapivat, Ciclopirox, Vemurafenib, Darunavir, Ketoconazole, Probenecid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94703, 'Succinylcholine', 'Minocycline', 'Moderate', 'Some drugs may enhance the effects of neuromuscular blocking agents.', 'DDInter', 'Observation for profound and prolonged respiratory depression and muscle weakness is recommended if these drugs must be used together.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94807/', '', 'Pipecuronium, Botulinum toxin type A, Doxacurium, Tubocurarine', 'Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Azelaic acid, Adapalene, Tigecycline, Sarecycline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94704, 'Sucralfate', 'Minocycline', 'Moderate', 'INTERVAL: Simultaneous administration of sucralfate may interfere with the absorption of tetracyclines and reduce their oral bioavailability. Sucralfate is an aluminum salt of a sulfated disaccharide. The aluminum moiety can dissociate at gastric pH and chelate with tetracyclines to form an insoluble complex that is poorly absorbed from the gastrointestinal tract. Reduced antibiotic efficacy may occur.', 'DDInter', 'To minimize the potential for interaction, tetracyclines should be administered at least 2 hours before sucralfate.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94808/', '', 'Tinidazole, Dexlansoprazole, Misoprostol, Rifabutin, Nizatidine, Esomeprazole, Ranitidine, Vonoprazan, Levofloxacin', 'Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Tigecycline, Eravacycline, Neomycin, Miconazole', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94705, 'Iron sucrose', 'Minocycline', 'Moderate', 'INTERVAL: Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of tetracyclines. The proposed mechanism is chelation of tetracyclines to the ferric ion component of sucroferric oxyhydroxide, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'Doxycycline should be administered at least 1 hour before sucroferric oxyhydroxide. Omadacycline administration with sucroferric oxyhydroxide should be separated by 4 hours. No dosing recommendations are available for use with other tetracyclines, although patients should consider following the same precaution.', 'Absorption', 'Doxycycline should be administered at least 1 hour before sucroferric oxyhydroxide.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94809/', '', 'Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Methylprednisolone, Azelaic acid, Adapalene, More', 'Cyanocobalamin, Folic acid, Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Difelikefalin, Cobicistat, Deferoxamine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94706, 'Teriflunomide', 'Minocycline', 'Major', 'The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.', 'DDInter', 'Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide''s active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94810/', '', 'Clindamycin, Vitamin A, Fluorometholone, Azelaic acid, Adapalene, Tetracycline, Oxytetracycline, Doxycycline, Omadacycline, Eravacycline, Demeclocycline, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94707, 'Theophylline', 'Minocycline', 'Moderate', 'Coadministration of a tetracycline may decrease theophylline plasma clearance and increase theophylline levels. Data are available for minocycline, tetracycline, and doxycycline, but are conflicting in some cases. This interaction appears to be more problematic if a tetracycline is administered for more than five days. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity.', 'DDInter', 'If these drugs are given concurrently, close clinical and laboratory monitoring of response and tolerance is recommended. Patients should be advised to notify their physician if they experience any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeats. It may be necessary to reduce theophylline dosage.', 'Metabolism', 'If these drugs are given concurrently, close clinical and laboratory monitoring of response and tolerance is recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94811/', '', 'Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline', 'Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Dapsone, Azelaic acid, Adapalene, Tigecycline, Sarecycline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94708, 'Tioguanine', 'Minocycline', 'Moderate', 'The concomitant or sequential use of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with thioguanine. A high risk of liver toxicity characterized by vascular endothelial damage has been reported with long-term continuous use of thioguanine, particularly in children receiving the drug as part of maintenance therapy for acute lymphoblastic leukemia and in other conditions associated with continuous use.', 'DDInter', 'The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Baseline and regular monitoring of hepatic function is recommended. Thioguanine therapy should be discontinued if there is evidence of toxic hepatitis or biliary stasis, as reversal of signs and symptoms of liver toxicity have been reported upon withdrawal. Early indications of liver toxicity are signs associated with portal hypertension such as thrombocytopenia out of proportion with neutropenia and splenomegaly. Elevations of liver enzymes have also been reported, but do not always occur.', 'Synergism', 'The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94812/', '', 'Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Pralatrexate, Fludarabine, Decitabine, More', 'Clindamycin, Vitamin A, Fluorometholone, Dapsone, Methylprednisolone, Azelaic acid, Adapalene, Tetracycline, Oxytetracycline, Doxycycline, Omadacycline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94709, 'Ticarcillin', 'Minocycline', 'Moderate', 'Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by penicillins. Antagonism is more likely when low doses of either agent are administered. Therapeutic failure may result.', 'DDInter', 'This combination should be avoided if possible.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94813/', '', 'Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Fluorometholone, Tretinoin, Dapsone, Methylprednisolone, Azelaic acid, Adapalene, Tigecycline, More', 'Tazobactam, Sulbactam', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94710, 'Torasemide', 'Minocycline', 'Minor', 'The coadministration of diuretics and tetracyclines may result in decreased renal function manifested by increases in serum creatinine and blood urea nitrogen (BUN). Usually, no clinical intervention is necessary, unless decreases in renal function occur. If renal function deteriorates, discontinuation of one or both agents may be necessary.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94814/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Mitapivat, Ciclopirox, Vemurafenib, Darunavir, Ketoconazole, Probenecid, More', 'Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Dapsone, Azelaic acid, Adapalene, Tigecycline, Sarecycline, Omadacycline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94711, 'Trabectedin', 'Minocycline', 'Moderate', 'Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'DDInter', 'The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.', 'Synergism', 'The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94815/', '', 'Clindamycin, Vitamin A, Fluorometholone, Methylprednisolone, Azelaic acid, Adapalene, Tetracycline, Oxytetracycline, Doxycycline, Omadacycline, Eravacycline, More', 'Vincristine, Cabazitaxel, Vinblastine, Paclitaxel, Topotecan, Teniposide, Irinotecan, Vinorelbine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94712, 'Tretinoin', 'Minocycline', 'Major', 'Concomitant use of vitamin A or related compounds (i.e., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign intracranial hypertension. These agents individually have been associated with the development of pseudotumor cerebri and may have additive effects during coadministration. The interaction has been suspected in reported cases involving the use of isotretinoin or vitamin A in combination with a tetracycline.', 'DDInter', 'Coadministration of most retinoids with tetracyclines is considered contraindicated. Patients treated with a retinoid or a tetracycline should be advised to discontinue the medication and notify their physician immediately if they develop early symptoms of pseudotumor cerebri such as headache, nausea, vomiting, visual disturbances, vision loss, and papilledema. Although intracranial hypertension typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. Therefore, prompt ophthalmologic evaluation should be performed if visual disturbances occur. Since intracranial pressure may remain elevated for weeks after drug cessation, patients should be monitored until they stabilize.', 'Synergism', 'Coadministration of most retinoids with tetracyclines is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94816/', '', 'Pertuzumab, Olaparib, Rucaparib, Bortezomib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, Sotorasib, More', 'Chloramphenicol, Azelaic acid, Fluorometholone, Tretinoin, Tigecycline, Miconazole, Clotrimazole, Epinephrine, Chlorhexidine, Neomycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94713, 'Triamterene', 'Minocycline', 'Minor', 'The coadministration of diuretics and tetracyclines may result in decreased renal function manifested by increases in serum creatinine and blood urea nitrogen (BUN). Usually, no clinical intervention is necessary, unless decreases in renal function occur. If renal function deteriorates, discontinuation of one or both agents may be necessary.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94817/', '', 'Eplerenone, Finerenone', 'Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Azelaic acid, Adapalene, Sarecycline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94714, 'Trichlormethiazide', 'Minocycline', 'Minor', 'The coadministration of diuretics and tetracyclines may result in decreased renal function manifested by increases in serum creatinine and blood urea nitrogen (BUN). Usually, no clinical intervention is necessary, unless decreases in renal function occur. If renal function deteriorates, discontinuation of one or both agents may be necessary.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94818/', '', 'Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Azelaic acid, Adapalene, Tigecycline, More', 'Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Mitapivat, Ciclopirox, Vemurafenib, Darunavir, Ketoconazole, Probenecid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94715, 'Tromethamine', 'Minocycline', 'Moderate', 'INTERVAL: Alkalinization of the urine may decrease the plasma concentration of some tetracyclines. The mechanism is not completely understood, but may involve increased renal elimination of tetracyclines when the urine becomes alkalinized.', 'DDInter', 'If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).', 'Excretion', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94819/', '', 'Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Methylprednisolone, Azelaic acid, More', 'Arginine, Sodium glycerophosphate, Sodium phosphate, monobasic, Sodium chloride, Potassium acetate, Ammonium chloride, Urea', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94716, 'Typhoid vaccine (live)', 'Minocycline', 'Major', 'INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.', 'DDInter', 'Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.', 'Others', 'Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94820/', '', 'Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Acetylsalicylic acid, Amphotericin B, Miconazole, Clotrimazole, Epinephrine, Chlorhexidine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94717, 'Vecuronium', 'Minocycline', 'Moderate', 'Some drugs may enhance the effects of neuromuscular blocking agents.', 'DDInter', 'Observation for profound and prolonged respiratory depression and muscle weakness is recommended if these drugs must be used together.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94821/', '', 'Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Dapsone, Azelaic acid, Adapalene, Tigecycline, Sarecycline, Omadacycline, More', 'Pipecuronium, Botulinum toxin type A, Doxacurium, Tubocurarine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94718, 'Verteporfin', 'Minocycline', 'Moderate', 'Concomitant use of verteporfin with other known photosensitizing agents may increase the risk of photosensitivity reactions. Medicinal products with known phototoxic or photoallergic potential include fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, and hypericin extracts (e.g., St John''s Wort).', 'DDInter', 'Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided. Patients should be advised to avoid exposure of skin or eyes to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 5 days after administration of verteporfin.', 'Synergism', 'Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94822/', '', 'Aflibercept, Bevacizumab', 'Clindamycin, Vitamin A, Dexamethasone, Chloramphenicol, Fluorometholone, Erythromycin, Methylprednisolone, Azelaic acid, Adapalene, Amphotericin B, Miconazole, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94719, 'Vitamin A', 'Minocycline', 'Major', 'Concomitant use of vitamin A or related compounds (i.e., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign intracranial hypertension. These agents individually have been associated with the development of pseudotumor cerebri and may have additive effects during coadministration. Both acute and chronic vitamin A intoxication have been identified as secondary causes of pseudotumor cerebri.', 'DDInter', 'Caution is advised if vitamin A is coadministered with tetracyclines. Concomitant use of most retinoids with tetracyclines is considered contraindicated. Patients treated with any of these agents should be advised to discontinue treatment and notify their physician immediately if they develop early symptoms of pseudotumor cerebri such as headache, nausea, vomiting, visual disturbances, vision loss, and papilledema. Although intracranial hypertension typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. Therefore, prompt ophthalmologic evaluation should be performed if visual disturbances occur. Since intracranial pressure may remain elevated for weeks after drug cessation, patients should be monitored until they stabilize.', 'Synergism', 'Caution is advised if vitamin A is coadministered with tetracyclines.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94823/', '', 'Alteplase, Ascorbic acid, Sirolimus, Potassium Iodide, Acetylcysteine, Nandrolone, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More', 'Clindamycin, Vitamin A, Dexamethasone, Chloramphenicol, Fluorometholone, Erythromycin, Dapsone, Methylprednisolone, Azelaic acid, Adapalene, Tigecycline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94720, 'Warfarin', 'Minocycline', 'Moderate', 'Tetracyclines may increase the hypoprothrombinemic effects of warfarin and similar anticoagulants. The mechanism of interaction has not been established, but may involve depression of plasma prothrombin activity or suppression of vitamin K-producing bacteria in the gastrointestinal tract, although the latter may be of limited clinical importance except in patients whose dietary intake of vitamin K is severely reduced.', 'DDInter', 'Caution is advised when warfarin and similar anticoagulants are used with tetracyclines. The INR should be checked frequently and the anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of tetracycline therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Others', 'Caution is advised when warfarin and similar anticoagulants are used with tetracyclines.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94824/', '', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More', 'Vitamin A, Azelaic acid, Fluorometholone, Adapalene', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94721, 'Zinc acetate', 'Minocycline', 'Moderate', 'INTERVAL: The bioavailability of oral tetracyclines may be significantly decreased during concurrent administration with zinc-containing products. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the zinc cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours. Doxycycline may be an appropriate alternative, since its absorption may not be significantly affected by zinc coadministration.', 'Absorption', 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94825/', '', 'Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Azelaic acid, Adapalene, Doxycycline, More', 'Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Betamethasone, Fluorometholone, Dexamethasone, Teduglutide, Lonafarnib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94722, 'Zinc chloride', 'Minocycline', 'Moderate', 'INTERVAL: The bioavailability of oral tetracyclines may be significantly decreased during concurrent administration with zinc-containing products. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the zinc cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours. Doxycycline may be an appropriate alternative, since its absorption may not be significantly affected by zinc coadministration.', 'Absorption', 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94826/', '', 'Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Azelaic acid, Adapalene, Doxycycline, More', 'Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Betamethasone, Fluorometholone, Dexamethasone, Arginine, Sodium glycerophosphate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94723, 'Zinc gluconate', 'Minocycline', 'Moderate', 'INTERVAL: The bioavailability of oral tetracyclines may be significantly decreased during concurrent administration with zinc-containing products. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the zinc cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours. Doxycycline may be an appropriate alternative, since its absorption may not be significantly affected by zinc coadministration.', 'Absorption', 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94827/', '', 'Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Azelaic acid, Adapalene, Doxycycline, More', 'Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Betamethasone, Fluorometholone, Dexamethasone, Sodium chloride, Sodium sulfate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94724, 'Zinc sulfate', 'Minocycline', 'Moderate', 'INTERVAL: The bioavailability of oral tetracyclines may be significantly decreased during concurrent administration with zinc-containing products. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the zinc cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours. Doxycycline may be an appropriate alternative, since its absorption may not be significantly affected by zinc coadministration.', 'Absorption', 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94828/', '', 'Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Azelaic acid, Adapalene, Doxycycline, More', 'Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Betamethasone, Fluorometholone, Dexamethasone, Sodium chloride, Sodium sulfate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94725, 'Isradipine', 'Amprenavir', 'Moderate', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by amprenavir.', 'DDInter', 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever amprenavir is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94829/', '', 'Clevidipine, Mibefradil, Celecoxib', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94726, 'Isradipine', 'Atracurium', 'Moderate', 'Some calcium channel blockers may enhance the neuromuscular blocking properties of nondepolarizing muscle relaxants. The mechanism is not known, but may involve blockage of calcium channels on skeletal muscle. Data are available for verapamil, diltiazem, nicardipine, atracurium, vecuronium, and pancuronium.', 'DDInter', 'Patients should be closely monitored for prolonged neuromuscular blockade. Reduced doses of muscle relaxants may be necessary. Profound neuromuscular blockade may be reversed by neostigmine or edrophonium.', 'Synergism', 'Patients should be closely monitored for prolonged neuromuscular blockade.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94830/', '', 'Clevidipine, Mibefradil, Nisoldipine, Celecoxib', 'Botulinum toxin type A', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94727, 'Isradipine', 'Berotralstat', 'Moderate', 'Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of CYP450 3A4 and/or 2D6. The mechanism is decreased clearance due to inhibition of CYP450 3A4 and 2D6 activity by berotralstat.', 'DDInter', 'Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94831/', '', 'Clevidipine, Celecoxib, Levamlodipine', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94728, 'Isradipine', 'Bismuth subsalicylate', 'Moderate', 'Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.', 'DDInter', 'Monitoring for altered blood pressure control is recommended.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94832/', '', 'Clevidipine, Mibefradil, Celecoxib', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94729, 'Isradipine', 'Boceprevir', 'Moderate', 'Coadministration with the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir and telaprevir, may increase the plasma concentrations and pharmacologic effects of calcium channel blockers, especially the dihydropyridines (e.g., amlodipine, felodipine, nicardipine, nifedipine, nisoldipine). The mechanism involves inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of most calcium channel blockers.', 'DDInter', 'Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with boceprevir or telaprevir. Dosage reduction may be required for the calcium channel blocker, particularly if it is a dihydropyridine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.', 'Metabolism', 'Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with boceprevir or telaprevir.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94833/', '', 'Clevidipine, Celecoxib', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94730, 'Isradipine', 'Bromfenac', 'Moderate', 'Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.', 'DDInter', 'Monitoring for altered blood pressure control is recommended.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94834/', '', 'Clevidipine, Mibefradil', 'Fluocinolone acetonide, Fluorometholone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94731, 'Isradipine', 'Butabarbital', 'Moderate', 'Barbiturates may increase the hepatic metabolism of some dihydropyridine calcium channel blockers by inducing CYP450 3A4 hepatic metabolism. The serum concentrations and effects of these calcium channel blockers may be significantly decreased.', 'DDInter', 'If concurrent administration cannot be avoided, the patient should be closely monitored for changes in pharmacologic effects whenever a barbiturate is initiated, discontinued or its dosage adjusted. An increased dosage of the calcium channel blocker may be necessary.', 'Metabolism', 'If concurrent administration cannot be avoided, the patient should be closely monitored for changes in pharmacologic effects whenever a barbiturate is initiated, discontinued or its dosage adjusted.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94835/', '', 'Suvorexant, Triazolam, Flurazepam, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Paraldehyde, Ramelteon, Lemborexant, Ethchlorvynol, More', 'Celecoxib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94732, 'Isradipine', 'Calcium carbonate', 'Moderate', 'Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.', 'DDInter', 'Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94836/', '', 'Celecoxib', 'Aluminum hydroxide, Magnesium oxide, Magaldrate, Magnesium hydroxide, Magnesium carbonate, Ascorbic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94733, 'Isradipine', 'Calcium chloride', 'Moderate', 'Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.', 'DDInter', 'Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94837/', '', 'Clevidipine, Mibefradil', 'Ascorbic acid, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94734, 'Isradipine', 'Calcium citrate', 'Moderate', 'Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.', 'DDInter', 'Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94838/', '', 'Clevidipine, Celecoxib', 'Ascorbic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94735, 'Isradipine', 'Calcium glubionate anhydrous', 'Moderate', 'Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.', 'DDInter', 'Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94839/', '', 'Clevidipine, Mibefradil, Celecoxib', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94736, 'Isradipine', 'Calcium glucoheptonate', 'Moderate', 'Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.', 'DDInter', 'Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94840/', '', 'Clevidipine, Mibefradil, Celecoxib', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94737, 'Isradipine', 'Calcium gluconate', 'Moderate', 'Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.', 'DDInter', 'Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94841/', '', 'Clevidipine, Celecoxib', 'Minoxidil, Deoxycholic acid, Pimecrolimus, Glycopyrronium, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Abrocitinib, Dupilumab, Tralokinumab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94738, 'Isradipine', 'Calcium glycerophosphate', 'Moderate', 'Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.', 'DDInter', 'Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94842/', '', 'Clevidipine, Mibefradil, Celecoxib', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94739, 'Isradipine', 'Calcium lactate', 'Moderate', 'Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.', 'DDInter', 'Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94843/', '', 'Clevidipine, Celecoxib', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94740, 'Isradipine', 'Carteolol', 'Moderate', 'Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers are used concomitantly with beta blockers, particularly in patients with ventricular or conduction abnormalities. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. The proposed mechanisms include additive slowing in AV conduction, reduced cardiac contractility secondary to beta-blockade, and decreased peripheral vascular resistance secondary to calcium channel blockade. In addition, some calcium channel blockers may inhibit the CYP450 metabolism of hepatically metabolized beta blockers, resulting in increased serum concentrations.', 'DDInter', 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary. The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', 'Metabolism, Synergism', 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94844/', '', 'Mibefradil', 'Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94741, 'Isradipine', 'Cerivastatin', 'Minor', 'Isradipine may increase the plasma clearance or decrease the absorption of lovastatin. Plasma lovastatin concentrations may be decreased. Although reduced clinical efficacy of lovastatin has not been demonstrated as a result of this interaction, data are limited. Reduced antihyperlipidemic effects should be anticipated. A similar reaction may occur with other HMG-CoA reductase inhibitors.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94845/', '', 'Nisoldipine, Nicardipine, Clevidipine, Nimodipine, Mibefradil', 'Gemfibrozil, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Lomitapide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94742, 'Isradipine', 'Chlorpromazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', 'DDInter', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94846/', '', 'Droperidol, Pimozide, Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94743, 'Isradipine', 'Clotrimazole', 'Moderate', 'Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g., amlodipine, felodipine, nicardipine, nifedipine, nisoldipine). The mechanism involves inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of most CCBs.', 'DDInter', 'Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with azole antifungal agents. Dosage reduction may be required for the calcium channel blocker, particularly if it is a dihydropyridine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.', 'Metabolism', 'Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with azole antifungal agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94847/', '', 'Selenium Sulfide, Thiabendazole, Ciclopirox, Griseofulvin, Terbinafine, Econazole, Flucytosine, Tioconazole, Chlorphenesin, Tetracycline, Minocycline, More', 'Clevidipine, Mibefradil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94744, 'Isradipine', 'Desflurane', 'Moderate', 'Calcium channel blockers may potentiate the cardiac depressant and hypotensive effects of volatile (halogenated) anesthetics, and vice versa, due to their similar pharmacologic action on the cardiovasculature. Serious consequences of this interaction may include cardiovascular collapse, ventricular impairment, and/or conduction disturbances, particularly in patients with underlying cardiac complications. The interaction may be more likely with verapamil and diltiazem due to their dromotropic and chronotropic effects.', 'DDInter', 'Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension. However, extreme care must be taken when administering halogenated anesthetics to patients under treatment with calcium channel blockers. Hemodynamic and electrocardiographic monitoring are recommended during the operation and postoperatively, and the dosage of one or both drugs adjusted as necessary.', 'Synergism', 'Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94848/', '', 'Clevidipine, Celecoxib', 'Remifentanil, Nitrous oxide, Propofol, Esketamine, Etomidate, Ketamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94745, 'Isradipine', 'Diflunisal', 'Moderate', 'Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.', 'DDInter', 'Monitoring for altered blood pressure control is recommended.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94849/', '', 'Clevidipine, Mibefradil', 'Ziconotide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94746, 'Isradipine', 'Dimenhydrinate', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94850/', '', 'Mibefradil, Nisoldipine, Celecoxib', 'Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94747, 'Isradipine', 'Doxacurium', 'Moderate', 'Some calcium channel blockers may enhance the neuromuscular blocking properties of nondepolarizing muscle relaxants. The mechanism is not known, but may involve blockage of calcium channels on skeletal muscle. Data are available for verapamil, diltiazem, nicardipine, atracurium, vecuronium, and pancuronium.', 'DDInter', 'Patients should be closely monitored for prolonged neuromuscular blockade. Reduced doses of muscle relaxants may be necessary. Profound neuromuscular blockade may be reversed by neostigmine or edrophonium.', 'Synergism', 'Patients should be closely monitored for prolonged neuromuscular blockade.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94851/', '', 'Clevidipine, Mibefradil, Nisoldipine, Celecoxib', 'Botulinum toxin type A', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94748, 'Isradipine', 'Echinacea', 'Moderate', 'Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.', 'DDInter', 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.', 'Metabolism', 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94852/', '', 'Clevidipine, Celecoxib', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94749, 'Isradipine', 'Edetate calcium disodium anhydrous', 'Moderate', 'Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.', 'DDInter', 'Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94853/', '', 'Clevidipine, Mibefradil, Celecoxib', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94750, 'Isradipine', 'Efavirenz', 'Moderate', 'Coadministration with efavirenz may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by efavirenz.', 'DDInter', 'Caution is advised if efavirenz must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever efavirenz is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if efavirenz must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94854/', '', 'Clevidipine', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94751, 'Isradipine', 'Emapalumab', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94855/', '', 'Clevidipine, Mibefradil, Celecoxib', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94752, 'Isradipine', 'Empagliflozin', 'Moderate', 'Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.', 'DDInter', 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.', 'Synergism', 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94856/', '', 'Celecoxib', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94753, 'Isradipine', 'Enalapril', 'Minor', 'Calcium channel blockers and angiotensin converting enzyme (ACE) inhibitors may have additive hypotensive effects. While these drugs are often safely used together, careful monitoring of the systemic blood pressure is recommended during coadministration, especially during the first one to three weeks of therapy.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94857/', '', 'Clevidipine, Nimodipine', 'Felodipine, Indapamide, Verapamil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94754, 'Isradipine', 'Encorafenib', 'Moderate', 'Coadministration with encorafenib may alter the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4, resulting in increased toxicity or decreased efficacy of these drugs.', 'DDInter', 'Concomitant use of encorafenib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.', 'Metabolism', 'Concomitant use of encorafenib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94858/', '', 'Clevidipine, Celecoxib', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94755, 'Isradipine', 'Enflurane', 'Moderate', 'Calcium channel blockers may potentiate the cardiac depressant and hypotensive effects of volatile (halogenated) anesthetics, and vice versa, due to their similar pharmacologic action on the cardiovasculature. Serious consequences of this interaction may include cardiovascular collapse, ventricular impairment, and/or conduction disturbances, particularly in patients with underlying cardiac complications. The interaction may be more likely with verapamil and diltiazem due to their dromotropic and chronotropic effects.', 'DDInter', 'Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension. However, extreme care must be taken when administering halogenated anesthetics to patients under treatment with calcium channel blockers. Hemodynamic and electrocardiographic monitoring are recommended during the operation and postoperatively, and the dosage of one or both drugs adjusted as necessary.', 'Synergism', 'Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94859/', '', 'Remifentanil, Nitrous oxide, Propofol, Esketamine, Etomidate, Ketamine', 'Clevidipine, Mibefradil, Celecoxib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94756, 'Isradipine', 'Entrectinib', 'Moderate', 'Coadministration with entrectinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by entrectinib. The interaction may be particularly important for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index.', 'DDInter', 'Caution may be advisable when entrectinib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, lovastatin, macrolide immunosuppressants, midazolam, sildenafil, simvastatin, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever entrectinib is added to or withdrawn from therapy.', 'Metabolism', 'Caution may be advisable when entrectinib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94860/', '', 'Clevidipine, Celecoxib', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94757, 'Isradipine', 'Enzalutamide', 'Major', 'Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of calcium channel blockers with potent CYP450 3A4 inducers should generally be avoided. If coadministration is necessary, pharmacologic response should be monitored more closely following the initiation or discontinuation of the CYP450 3A4 inducer, and the CCB dosage adjusted accordingly.', 'Metabolism', 'Concomitant use of calcium channel blockers with potent CYP450 3A4 inducers should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94861/', '', 'Clevidipine', 'Darolutamide, Tamoxifen, Anastrozole, Toremifene, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94758, 'Isradipine', 'Epoprostenol', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', 'DDInter', 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94862/', '', 'Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94759, 'Isradipine', 'Erdafitinib', 'Moderate', 'Coadministration with erdafitinib may alter the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme, resulting in increased toxicity or decreased efficacy of these drugs.', 'DDInter', 'Concomitant use of erdafitinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94863/', '', 'Clevidipine, Celecoxib', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94760, 'Isradipine', 'Ertugliflozin', 'Moderate', 'Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.', 'DDInter', 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.', 'Synergism', 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94864/', '', 'Celecoxib', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94761, 'Isradipine', 'Erythromycin', 'Moderate', 'Coadministration of isradipine and erythromycin or clarithromycin may increase isradipine serum concentrations. The presumed mechanism is inhibition of CYP450 3A4 metabolism by the macrolide antibiotics.', 'DDInter', 'When macrolide antibiotics are coadministered with isradipine, patients should be monitored for adverse effects such as flushing, ankle edema, or palpitations.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94865/', '', 'Clindamycin, Troleandomycin, Dirithromycin, Azithromycin, Lincomycin, Minocycline, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, More', 'Clevidipine, Nimodipine, Nisoldipine, Nicardipine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94762, 'Isradipine', 'Esmolol', 'Moderate', 'Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers are used concomitantly with beta blockers, particularly in patients with ventricular or conduction abnormalities. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. The proposed mechanisms include additive slowing in AV conduction, reduced cardiac contractility secondary to beta-blockade, and decreased peripheral vascular resistance secondary to calcium channel blockade. In addition, some calcium channel blockers may inhibit the CYP450 metabolism of hepatically metabolized beta blockers, resulting in increased serum concentrations.', 'DDInter', 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary. The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', 'Metabolism, Synergism', 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94866/', '', 'Mibefradil', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94763, 'Isradipine', 'Etanercept', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94867/', '', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, More', 'Clevidipine, Mibefradil, Celecoxib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94764, 'Isradipine', 'Ethotoin', 'Moderate', 'Diltiazem and verapamil may increase plasma phenytoin levels. Toxicity has been reported. The proposed mechanism is inhibition of CYP450 3A4 metabolism. In addition, phenytoin may significantly decrease calcium channel blocker (CCB) serum levels by inducing first-pass metabolism and the systemic clearance. Other hydantoins may participate in these interactions as well.', 'DDInter', 'Close clinical and laboratory observation for evidence of altered effect of both drugs is recommended if a CCB and a hydantoin must be used together. Patients should be advised to notify their physician if they experience symptoms of phenytoin toxicity (e.g., drowsiness, visual disturbances, change in mental status, seizures, nausea, or ataxia) or loss of effect of their CCB.', 'Metabolism', 'Close clinical and laboratory observation for evidence of altered effect of both drugs is recommended if a CCB and a hydantoin must be used together.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94868/', '', 'Clevidipine, Mibefradil, Celecoxib', 'Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Levetiracetam, Tiagabine, Rufinamide, Paramethadione, Perampanel, Ganaxolone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94765, 'Isradipine', 'Etodolac', 'Moderate', 'Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.', 'DDInter', 'Monitoring for altered blood pressure control is recommended.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94869/', '', 'Clevidipine, Mibefradil', 'Phenylbutazone, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94766, 'Isradipine', 'Etravirine', 'Moderate', 'Coadministration with etravirine may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by etravirine.', 'DDInter', 'Caution is advised if etravirine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever etravirine is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if etravirine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94870/', '', 'Clevidipine', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94767, 'Isradipine', 'Fedratinib', 'Moderate', 'Coadministration of fedratinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C19, or 2D6 isoenzymes.', 'DDInter', 'Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.', 'Metabolism', 'Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94871/', '', 'Clevidipine, Celecoxib', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94768, 'Isradipine', 'Fenoldopam', 'Moderate', 'The use of fenoldopam with other hypotensive agents has not been studied. However, these combinations would theoretically increase the risk of severe symptomatic hypotension.', 'DDInter', 'Caution is strongly advised during concurrent use. Inpatient monitoring of the heart rate and blood pressure is recommended. Sublingual nitroglycerin has been used safely with fenoldopam.', 'Synergism', 'Caution is strongly advised during concurrent use.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94872/', '', 'Mibefradil, Celecoxib', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Isoprenaline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94769, 'Isradipine', 'Fenoprofen', 'Moderate', 'Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.', 'DDInter', 'Monitoring for altered blood pressure control is recommended.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94873/', '', 'Clevidipine, Mibefradil', 'Phenylbutazone, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94770, 'Isradipine', 'Fingolimod', 'Moderate', 'The risk of bradycardia and atrioventricular (AV) block may be increased during initiation of fingolimod treatment in patients receiving beta-blockers, calcium channel blockers, digitalis, or other drugs that can slow the heart rate or AV conduction such as alectinib, atazanavir, flecainide, ivabradine, lacosamide, lithium, mefloquine, moricizine, propafenone, succinylcholine, thalidomide, H2-receptor antagonists, tricyclic antidepressants, and anticholinesterase or cholinergic agents.', 'DDInter', 'Fingolimod has not been adequately studied in patients receiving other drugs that can slow the heart rate or AV conduction. Close monitoring is recommended during initiation of fingolimod treatment in these patients. The first dose should always be administered in a setting where resources to appropriately manage symptomatic bradycardia are available.', 'Synergism', 'Fingolimod has not been adequately studied in patients receiving other drugs that can slow the heart rate or AV conduction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94874/', '', 'Celecoxib', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94771, 'Isradipine', 'Fluconazole', 'Moderate', 'Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g., amlodipine, felodipine, nicardipine, nifedipine, nisoldipine). The mechanism involves inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of most CCBs.', 'DDInter', 'Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with azole antifungal agents. Dosage reduction may be required for the calcium channel blocker, particularly if it is a dihydropyridine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.', 'Metabolism', 'Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with azole antifungal agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94875/', '', 'Tinidazole, Tetracycline, Cefepime, Norfloxacin, Ciprofloxacin, Metronidazole, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, More', 'Clevidipine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94772, 'Isradipine', 'Fludrocortisone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', 'DDInter', 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Patients on prolonged (i.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94876/', '', 'Nimodipine', 'Fluocinolone acetonide, Fluocinolone acetonide, Fluorometholone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94773, 'Isradipine', 'Fluoxetine', 'Moderate', 'Coadministration of fluoxetine with calcium channel blockers may increase their plasma concentrations and the risk of side effects. The mechanism is reduced clearance of the calcium channel blocker due to inhibition of CYP450 3A4-mediated metabolism by fluoxetine. Reports exist for nifedipine, nimodipine, and verapamil. Theoretically, the interaction may also occur with other calcium channel blockers that are CYP450 3A4 substrates.', 'DDInter', 'Monitoring of clinical response and tolerance, including blood pressure, is recommended if fluoxetine is used in combination with calcium channel blockers that are metabolized by CYP450 3A4. Dose reductions may be considered, if necessary. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.', 'Metabolism', 'Monitoring of clinical response and tolerance, including blood pressure, is recommended if fluoxetine is used in combination with calcium channel blockers that are metabolized by CYP450 3A4.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94877/', '', 'Clevidipine', 'Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Amoxapine, Imipramine, Esketamine, Desipramine, Trimipramine, Oxitriptan, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94774, 'Isradipine', 'Fluphenazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', 'DDInter', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94878/', '', 'Droperidol, Pimozide, Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94775, 'Isradipine', 'Flurbiprofen', 'Moderate', 'Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.', 'DDInter', 'Monitoring for altered blood pressure control is recommended.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94879/', '', 'Clevidipine, Mibefradil', 'Tolazoline, Dimethyl sulfoxide, Phenylbutazone, Phenylbutazone, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Lidocaine, Bacitracin, Chlorhexidine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94776, 'Isradipine', 'Fluvastatin', 'Minor', 'Isradipine may increase the plasma clearance or decrease the absorption of lovastatin. Plasma lovastatin concentrations may be decreased. Although reduced clinical efficacy of lovastatin has not been demonstrated as a result of this interaction, data are limited. Reduced antihyperlipidemic effects should be anticipated. A similar reaction may occur with other HMG-CoA reductase inhibitors.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94880/', '', 'Nisoldipine, Nicardipine, Clevidipine, Levamlodipine, Nifedipine, Nimodipine', 'Gemfibrozil, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Lomitapide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94777, 'Isradipine', 'Fluvoxamine', 'Moderate', 'Coadministration with fluvoxamine may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to competitive inhibition of CYP450 3A4 activity by fluvoxamine.', 'DDInter', 'Caution is advised if fluvoxamine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fluvoxamine is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if fluvoxamine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94881/', '', 'Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Amoxapine, Imipramine, Esketamine, Desipramine, Trimipramine, Oxitriptan, More', 'Clevidipine, Levamlodipine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94778, 'Isradipine', 'Fosamprenavir', 'Moderate', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by amprenavir.', 'DDInter', 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever amprenavir is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94882/', '', 'Clevidipine', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94779, 'Isradipine', 'Fosaprepitant', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', 'DDInter', 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94883/', '', 'Clevidipine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94780, 'Isradipine', 'Fosinopril', 'Minor', 'Calcium channel blockers and angiotensin converting enzyme (ACE) inhibitors may have additive hypotensive effects. While these drugs are often safely used together, careful monitoring of the systemic blood pressure is recommended during coadministration, especially during the first one to three weeks of therapy.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94884/', '', 'Clevidipine, Nimodipine', 'Felodipine, Indapamide, Verapamil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94781, 'Isradipine', 'Fosphenytoin', 'Major', 'Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized by the isoenzyme.', 'DDInter', 'Concomitant use of calcium channel blockers with potent CYP450 3A4 inducers should generally be avoided. If coadministration is necessary, pharmacologic response should be monitored more closely following the initiation or discontinuation of the CYP450 3A4 inducer, and the CCB dosage adjusted accordingly.', 'Metabolism', 'Concomitant use of calcium channel blockers with potent CYP450 3A4 inducers should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94885/', '', 'Clevidipine, Mibefradil, Nisoldipine', 'Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Levetiracetam, Tiagabine, Rufinamide, Paramethadione, Perampanel, Ganaxolone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94782, 'Isradipine', 'Fostamatinib', 'Moderate', 'Coadministration with fostamatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine and/or liver due to inhibition of CYP450 3A4-mediated metabolism and P-gp-mediated efflux by fostamatinib.', 'DDInter', 'Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostamatinib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94886/', '', 'Clevidipine, Celecoxib', 'Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94783, 'Isradipine', 'Gadopentetic acid', 'Moderate', 'Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media. The mechanism is unknown.', 'DDInter', 'Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension. Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.', 'Synergism', 'Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94887/', '', 'Mibefradil, Celecoxib', 'Gadoversetamide, Gadobutrol, Gadofosveset trisodium, Gadobenic acid, Gadodiamide, Gadoteridol, Ferumoxsil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94784, 'Isradipine', 'Gadoteric acid', 'Moderate', 'Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media. The mechanism is unknown.', 'DDInter', 'Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension. Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.', 'Synergism', 'Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94888/', '', 'Mibefradil, Celecoxib', 'Gadoversetamide, Gadobutrol, Gadofosveset trisodium, Gadobenic acid, Gadodiamide, Gadoteridol, Ferumoxsil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94785, 'Isradipine', 'Gadoxetic acid', 'Moderate', 'Coadministration of calcium channel blockers may increase the cardiovascular effects of ionic X-ray contrast media. The mechanism is unknown.', 'DDInter', 'Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension. Use of a nonionic contrast agent, such as iopamidol, may be considered instead of ionic contrast where clinically appropriate.', 'Synergism', 'Patients taking calcium channel blockers should be closely monitored for increased cardiovascular effects of ionic X-ray contrast media, such as hypotension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94889/', '', 'Celecoxib', 'Gadoversetamide, Gadobutrol, Gadofosveset trisodium, Gadobenic acid, Gadodiamide, Gadoteridol, Ferumoxsil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94786, 'Isradipine', 'Galantamine', 'Moderate', 'Since acetylcholinesterase inhibitors can cause bradycardia and heart block due to vagotonic effects on the sinoatrial and atrioventricular nodes, additive effects may occur with other agents that also possess bradycardic effects such as beta-blockers, calcium channel blockers, digitalis, some protease inhibitors (atazanavir, lopinavir-ritonavir, saquinavir), amiodarone, dronedarone, moricizine, lacosamide, and mefloquine.', 'DDInter', 'Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs. Patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', 'Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94890/', '', 'Memantine, Ginkgo biloba, Aducanumab', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94787, 'Isradipine', 'Garlic', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94891/', '', 'Celecoxib', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94788, 'Isradipine', 'Golimumab', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94892/', '', 'Clevidipine, Mibefradil, Celecoxib', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94789, 'Isradipine', 'Grepafloxacin', 'Moderate', 'Based on in vitro inhibition data, coadministration with grepafloxacin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by grepafloxacin.', 'DDInter', 'Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever grepafloxacin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94893/', '', 'Clevidipine, Mibefradil', 'Enoxacin, Gatifloxacin, Norfloxacin, Levofloxacin, Nalidixic acid, Gemifloxacin, Ciprofloxacin, Lomefloxacin, Moxifloxacin, Cinoxacin, Trovafloxacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94790, 'Isradipine', 'Guanfacine', 'Moderate', 'Use of guanfacine in combination with antihypertensive agents may result in additive pharmacodynamic effects such as hypotension and syncope.', 'DDInter', 'Caution is advised during coadministration of these agents. Dosage adjustments may be required and hemodynamic responses should be monitored during concomitant therapy. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.', 'Synergism', 'Caution is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94894/', '', 'Celecoxib', 'Rauwolfia serpentina root, Reserpine, Methyldopa, Deserpidine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94791, 'Isradipine', 'Guselkumab', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94895/', '', 'Clevidipine, Mibefradil, Celecoxib', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94792, 'Isradipine', 'Haloperidol', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', 'DDInter', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94896/', '', 'Droperidol, Pimozide, Pimavanserin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94793, 'Isradipine', 'Halothane', 'Moderate', 'Calcium channel blockers may potentiate the cardiac depressant and hypotensive effects of volatile (halogenated) anesthetics, and vice versa, due to their similar pharmacologic action on the cardiovasculature. Serious consequences of this interaction may include cardiovascular collapse, ventricular impairment, and/or conduction disturbances, particularly in patients with underlying cardiac complications. The interaction may be more likely with verapamil and diltiazem due to their dromotropic and chronotropic effects.', 'DDInter', 'Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension. However, extreme care must be taken when administering halogenated anesthetics to patients under treatment with calcium channel blockers. Hemodynamic and electrocardiographic monitoring are recommended during the operation and postoperatively, and the dosage of one or both drugs adjusted as necessary.', 'Synergism', 'Discontinuation of calcium channel blockers prior to surgery is generally not recommended because of the rebound effect in patients with coronary heart disease or arterial hypertension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94897/', '', 'Clevidipine, Celecoxib', 'Remifentanil, Nitrous oxide, Propofol, Esketamine, Etomidate, Ketamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94794, 'Isradipine', 'Diamorphine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94898/', '', 'Mibefradil, Celecoxib', 'Acamprosate, Naltrexone, Varenicline, Disulfiram, Levacetylmethadol, Nalmefene, Nicotine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94795, 'Isradipine', 'Hydromorphone', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94899/', '', 'Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94796, 'Isradipine', 'Idelalisib', 'Moderate', 'Coadministration with idelalisib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. Idelalisib has been shown to be a potent inhibitor of this isoenzyme.', 'DDInter', 'Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.g., antiarrhythmics, anticonvulsants, antineoplastics, immunosuppressants) or those that are considered sensitive substrates (e.g., ergot derivatives, statins, oral midazolam, triazolam). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever idelalisib is added to or withdrawn from therapy, if coadministration is required.', 'Metabolism', 'Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94900/', '', 'Clevidipine', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94797, 'Isradipine', 'Iloperidone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', 'DDInter', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94901/', '', 'Mibefradil, Celecoxib', 'Droperidol, Pimozide, Pimavanserin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94798, 'Isradipine', 'Iloprost', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', 'DDInter', 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94902/', '', 'Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94799, 'Isradipine', 'Imatinib', 'Moderate', 'Coadministration with imatinib may increase the plasma concentrations of drugs that are substrates of CYP450 2C9, 2D6 and/or 3A4. The mechanism is decreased clearance due to inhibition of these isoenzymes by imatinib.', 'DDInter', 'Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever imatinib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94903/', '', 'Clevidipine', 'Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (94800, 'Isradipine', 'Indinavir', 'Moderate', 'Coadministration with indinavir may increase the plasma concentrations and pharmacologic effects of calcium channel blockers, especially the dihydropyridines (e.g., amlodipine, felodipine, nicardipine, nifedipine, nisoldipine). The mechanism involves indinavir inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of most calcium channel blockers.', 'DDInter', 'Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with indinavir. Dosage reduction may be required for the calcium channel blocker, particularly if it is a dihydropyridine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.', 'Metabolism', 'Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with indinavir.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/94904/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More', 'Clevidipine', 1767369485);
